CAMP4 Therapeutics (Nasdaq:CAMP) granted non-qualified stock options to three new employees under Nasdaq Listing Rule 5635(c)(4). The inducement awards cover an aggregate 39,000 shares at an exercise price of $3.96 per share, equal to the June 15, 2026 closing price.
The options have a 10-year term and vest over four years: 25% after one year of employment, then the remainder in 36 equal monthly installments, subject to continued service. The grants are issued under CAMP4’s 2026 Inducement Plan and related stock option agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CAMP
+1.69%
+1.69%Session close to close
In the Jun 22 session, CAMP gained 1.69%, reflecting a mild positive market reaction.
This announcement details 39,000 inducement stock options granted under Nasdaq rules at an exercise ...
Analysis
This announcement details 39,000 inducement stock options granted under Nasdaq rules at an exercise price of $3.96, a routine hiring tool. Prior similar grants produced only modest stock moves, though dilution from equity programs and the shelf remains a background risk to monitor.
Key Figures
Inducement options granted:39,000 sharesNumber of new hires:3 employeesExercise price:$3.96 per share+4 more
7 metrics
Inducement options granted39,000 sharesAggregate non-qualified stock options to three new employees on June 15, 2026
Number of new hires3 employeesRecipients of inducement non-qualified stock options
Exercise price$3.96 per shareEqual to CAMP4’s common stock closing price on the June 15, 2026 grant date
Option term10 yearsDuration of each non-qualified stock option under the inducement grants
Vesting period4 yearsInducement options vest over four years, subject to continued service
Initial vesting cliff25% at 1 yearFirst tranche vests on the one-year anniversary of employment start date
Subsequent vesting schedule36 monthly installmentsRemaining option shares vest in equal monthly installments after year one
"granted non-qualified stock options to purchase an aggregate of 39,000 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
nasdaq listing rule 5635(c)(4)regulatory
"as an inducement material ... in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"an exercise price per share of $3.96, which is equal to the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
inducement grantsregulatory
"The Inducement Grants each have a ten-year term and an exercise price"
Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.
CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company’s common stock to three newly hired employees of the Company, each as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).
The Inducement Grants each have a ten-year term and an exercise price per share of $3.96, which is equal to the closing price of CAMP4’s common stock as of the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service with CAMP4 through the applicable vesting dates. Each Inducement Grant was granted pursuant to, and is subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable non-qualified stock option agreement.
About CAMP4 Therapeutics CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
What inducement stock option grants did CAMP4 Therapeutics (NASDAQ:CAMP) announce on June 19, 2026?
CAMP4 Therapeutics announced non-qualified stock options for an aggregate 39,000 shares as inducement grants to three new employees. According to CAMP4, these options were approved on June 15, 2026 under Nasdaq Listing Rule 5635(c)(4) as material to each employee’s hiring.
What is the exercise price of the CAMP4 Therapeutics (CAMP) inducement options granted June 15, 2026?
The inducement options have an exercise price of $3.96 per share. According to CAMP4, this price equals the closing price of CAMP4 common stock on the June 15, 2026 grant date used for these non-qualified stock option awards.
How do CAMP4 Therapeutics (CAMP) inducement stock options vest for the three new employees?
The inducement options vest over four years. According to CAMP4, 25% of each grant vests on the one-year anniversary of the employee’s first day, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service.
What is the term length of the CAMP4 Therapeutics (CAMP) inducement stock options?
Each inducement stock option has a 10-year term from the grant date. According to CAMP4, the non-qualified options were granted on June 15, 2026 and remain exercisable during this period, subject to vesting and the applicable stock option agreement.
Under what plan were the CAMP4 Therapeutics (CAMP) June 2026 inducement grants issued?
The June 2026 inducement grants were issued under CAMP4’s 2026 Inducement Plan. According to CAMP4, each non-qualified stock option is also governed by an applicable stock option agreement outlining specific terms and conditions for the new employee recipients.
